Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $117.86 USD
Change Today -0.04 / -0.03%
Volume 9.2M
GILD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Xetra
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GILD) Snapshot

Open
$118.97
Previous Close
$117.90
Day High
$119.00
Day Low
$117.12
52 Week High
06/24/15 - $123.37
52 Week Low
12/23/14 - $85.95
Market Cap
173.2B
Average Volume 10 Days
11.8M
EPS TTM
$9.59
Shares Outstanding
1.5B
EX-Date
09/14/15
P/E TM
12.3x
Dividend
$1.72
Dividend Yield
0.36%
Current Stock Chart for GILEAD SCIENCES INC (GILD)

gilead sciences inc (GILD) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

7,000 Employees
Last Reported Date: 02/25/15
Founded in 1987

gilead sciences inc (GILD) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $797.6K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $920.6K
Executive Vice President of Corporate & Medic...
Total Annual Compensation: $814.3K
Compensation as of Fiscal Year 2014.

gilead sciences inc (GILD) Key Developments

Gilead Eyes Acquisitions

Gilead Sciences Inc. (NasdaqGS:GILD) is looking for acquisitions. The company believes that diversification through key and potentially transformative acquisitions will shore up revenue generation in the longer-term. The company will make a potentially transformative acquisition in the oncology or liver disease area by the end of 2016.

Gilead Sciences Inc. Reports Earnings Results for the Second Quarter of 2015; Revised Earnings Guidance for the Full Year 2015

Gilead Sciences Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $8,244 million against $6,535 million a year ago. Income from operations was $5,616 million against $4,412 million a year ago. Income before provision for income taxes was $5,511 million against $4,306 million a year ago. Net income attributable to the company was $4,492 million or $2.92 per diluted share against $3,656 million or $2.20 per diluted share a year ago. Non-GAAP net income attributable to the company was $4,845 million or $3.15 per diluted share against $3,929 million or $3.15 per diluted share a year ago. During the second quarter of 2015, the company generated $5.7 billion in operating cash flow. For the second quarter, the company reported total revenues of $15,838 million against $11,534 million a year ago. Income from operations was $10,987 million against $7,455 million a year ago. Income before provision for income taxes was $10,750 million against $7,255 million a year ago. Net income attributable to the company was $8,825 million or $5.68 per diluted share against $5,883 million or $3.52 per diluted share a year ago. Non-GAAP net income attributable to the company was $9,449 million or $6.08 per diluted share against $6,417 million or $3.84 per diluted share a year ago. For the year 2015, the company expected the net product sales to be in the range of $29,000 million- $30,000 million compared to previous guidance of $28,000 million - $29,000 million. Effective tax rate to be 17.0% - 18.0% compared previous guidance of to 18.0% - 20.0%. It kept its earnings per share forecast at 82 cents to 87 cents per share.

Gilead Sciences, Inc. Declares Dividend for the Third Quarter of 2015, Payable on September 29, 2015

Gilead Sciences Inc. announced that the company’s Board of Directors has declared a cash dividend of $0.43 per share of common stock for the third quarter of 2015. The dividend is payable on September 29, 2015, to stockholders of record at the close of business on September 16, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $117.86 USD -0.04

GILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.01 USD -0.15
Amgen Inc $176.59 USD +4.90
GlaxoSmithKline PLC 1,396 GBp +7.00
Merck & Co Inc $58.96 USD +0.44
Sanofi €97.97 EUR +0.20
View Industry Companies
 

Industry Analysis

GILD

Industry Average

Valuation GILD Industry Range
Price/Earnings 12.4x
Price/Sales 5.9x
Price/Book 10.4x
Price/Cash Flow 11.5x
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.